{
  "docId": "019de076-0bfb-77a4-9766-824e83d61c36",
  "docSlug": "78f42e9d8d70fea2dc2370a17955f7e7",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 52,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 20,
  "notes": "The table uses a green/white color coding to highlight positive attributes of NVL-520 compared to competitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/11",
  "deckHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36",
  "deckJsonHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json",
  "deckAnchorHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.045,
        "w": 0.855,
        "x": 0.076,
        "y": 0.865
      },
      "kind": "disclaimer",
      "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-520. Clinical investigation of NVL-520 is ongoing.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc821116-8d8f-413c-9474-2b5b74e4c066",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.605,
        "w": 0.862,
        "x": 0.069,
        "y": 0.25
      },
      "kind": "table",
      "text": "Comparison matrix of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across 4 criteria.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41dd9bab-1336-4426-8ccf-f4513cf1772f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.063,
        "w": 0.191,
        "x": 0.076,
        "y": 0.115
      },
      "kind": "title",
      "text": "NVL-520",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34c55c45-ae25-4edb-a887-11dbe22f2f68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.026,
        "w": 0.505,
        "x": 0.076,
        "y": 0.188
      },
      "kind": "title",
      "text": "Differentiated Product Candidate for ROS1-positive NSCLC Patients",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a3aaf80-8873-4916-9f5d-8112724f81ba",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "9ec700cc-ed64-4de6-a729-abd6041a02a6",
      "evidence": "table/data: Comparison matrix of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across 4 criteria.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "1f6251ff-1208-4845-a800-a95cf462103c",
      "evidence": "The slide presents a structured grid comparing a lead product candidate against competitors across specific attributes.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 12,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "65aac5b7-e703-47fe-855e-79b350b26916",
      "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions",
      "position": 0,
      "objective": "What is the cost of not addressing drug resistance in cancer treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}